INTRODUCTION
Neutrophils are an essential component of the innate immune system, with a primary role in the clearance of extracellular pathogens (1) . Both localization and neutralization of microorganisms are important neutrophil functions that are orchestrated by specific inflammatory mediators released from the site of infection (2, 3) . In particular, chemoattractants and chemokine gradients are major neutrophil guidance signals, whereas the migration of neutrophils from the vasculature to inflammatory sites is mediated by adhesion proteins, including P-and E-selectins and integrin ligands such as vascular cell adhesion molecule 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1) and ICAM-2 on endothelium (2, 4) . Several mechanisms are involved in bacterial killing by neutrophils. For example, release of antimicrobial peptides, generation of reactive nitrogen and oxygen species (ROS/RNS), as well as production of hypochlorous acid by myeloperoxidase, are utilized by neutrophils to kill invading microorganisms (5, 6) . In addition to phagocytosis and killing internalized microorganisms, neutrophils also can release DNA and DNA-associated proteins to form extracellular traps to prevent bacterial dissemination (7, 8) .
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Beside the central roles that NADPHoxidase and ROS occupy in killing microorganisms, enhanced propagation and dissemination of bacteria are associated with loss of neutrophil ability to reach the site of infection (16, 17) . In sepsis, such alterations in neutrophil function are a result of disrupted chemokine signaling and expression of adhesion molecules (18) (19) (20) (21) . For example, the appearance of detectable levels of the bacterial products lipopolysaccharide (LPS) or lipoteichoic acid in the circulation of severely infected patients is associated with diminished neutrophil chemotaxis, including neutrophil response to interleukin 8 (IL-8), macro phage inflammatory protein 2 (MIP-2), or keratinocyte-derived chemokine (KC). In spite of progress in understanding mechanisms responsible for the inhibition of neutrophil chemotaxis, pharmacologic approaches to prevent or restore neutrophil chemotaxis and bacterial eradication are not available.
Metformin is commonly used in patients with non-insulin-dependent diabetes mellitus to lower blood glucose concentrations and to improve insulin sensitivity (22) . Metformin has been shown to prevent cardiovascular complications associated with diabetes and obesity through mechanisms that presumably involve inhibition of adipose tissue lipolysis, reduction of circulating levels of free fatty acids, and inhibition of low density lipoprotein production (23, 24) . Although metformin has a broad spectrum of effects, inhibition of mitochondrial complex I and activation of 5' adenosine monophosphate-activated protein kinase (AMPK) appear to be major mechanisms of its action (25, 26) . Recent studies have shown that besides their ability to regulate cellular metabolism (27) , metformin and other AMPK activators can decrease the severity of organ injury in acute inflammatory states (28) , including LPS-induced liver injury or acute lung injury (29, 30) . Metformin, berberine or aminoimidazole carboxamide ribonucleotide (AICAR) were all shown to diminish activation of the tolllike receptor 4 (TLR4)/NF-κB signaling cascade, as well as to release of proinflammatory mediators of neutrophils and macrophages, and also to enhance endothelial integrity in vitro and in models for sepsis (31) (32) (33) (34) (35) (36) . In addition, metformin enhances host defense mechanisms by facilitating the chemotaxis and maturation of T cells (37, 38) . Besides its antiinflammatory actions, activated AMPK was recently shown to increase the phagocytic ability of macrophages (39) . Although these studies revealed a beneficial effect of metformin in acute inflammatory conditions, there is little information concerning the ability of metformin or other AMPK activators to alter primary innate immune responses, and particularly bacterial eradication. In this study, we examined the hypothesis that AMPK activation may affect fundamental neutrophil functions, including chemotaxis and bacterial killing.
MATERIALS AND METHODS

Mice
Male C57BL/6 mice were purchased from the National Cancer InstituteFrederick (Frederick, MD, USA). Male mice, 8 to 10 wks of age, were used for experiments. The mice were kept on a 12-h light:dark cycle with free access to food and water. All experiments were conducted in accordance with protocols approved by the University of Alabama at Birmingham Animal Care and Use Committee.
Reagents and Antibodies
W-peptide was purchased from Phoenix Pharmaceuticals (Burlingame, CA, USA). Metformin, berberine and IκB kinase (IKK) inhibitor PS-1145 were obtained from Sigma-Aldrich (St. Louis, MO, USA). Compound C and rapamycin were purchased from Calbiochem (La Jolla, CA, USA). Antibodies for phosphoThr172-AMPK, total AMPK, phosphoSer240/244-rpS6, total rpS6, 4E-BP1, and IκBα were purchased from Cell Signaling 
Neutrophil Isolation and Culture
Bone marrow neutrophils were isolated as described previously (31, 40) . Neutrophil purity was consistently greater than 97%, as determined by WrightGiemsa-stained cytospin preparations. Neutrophils were cultured in RPMI 1640 medium containing 0.5% or 5% fetal bovine serum (FBS) and treated as indicated in the figure legends. Neutrophil viability under experimental conditions was determined using trypan blue staining and was consistently greater than 95%.
HL-60 Cell Culture and Differentiation
The HL-60 cell line was obtained from American Type Culture Collection and cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, penicillin (100 U/mL), streptomycin (25 μg/mL) and L-glutamine (1 mmol/L). To obtain differentiated cells, HL-60 cells were cultured in medium containing dimethyl sulfoxide (DMSO) (1.3%) for four consecutive days (41) . Differentiated cells were then used for small interfering RNA (siRNA) treatment and IL-8 mediated chemotaxis.
siRNA Knockdown of AMPKα1
Differentiated HL-60 cells were incubated with specific siRNA (1 μmol/L) to AMPKα1, as described previously (41) .
Briefly, cells (3.5 × 10 6 /well) in 12-well plates were incubated in Accell medium (serum free) containing siRNA (1 μmol/L) to AMPKα1 for 72 h. During incubation with siRNA, the cell culture medium was supplemented with 1.3% DMSO to maintain differentiation of the HL-60 cells. The cells were then subjected to Western blot analysis of AMPK or transwell migration assay.
Transwell Migration Assay
Transwell migration assay was performed using 24-well cell plate BD Falcon cell culture inserts (Translucent PET Membrane, BD Biosciences). Briefly, bone marrow neutrophils (10 6 cells/well) or differentiated HL-60 cells in 300 μL of RPMI 1640 medium (5% FBS) were added to the upper reservoir, whereas W-peptide or IL-8 in culture medium (800 μL) was placed in the lower reservoir of transmigration chamber. In all experiments, chemotaxis was determined after neutrophils or HL-60 cells were allowed to migrate for 60 min at 37°C followed by imaging the cells in the lower reservoir (41) . Each condition was tested three or more times.
Measurement of Cell Velocity
Bone marrow neutrophils pretreated as described in figure legends and then loaded into the μ-slide for chemotaxis assay (Ibidi). Cell migration was initiated by inclusion of W-peptide (50 nmol/L) to create a concentration gradient. Migration was recorded by imaging cells with 1 min intervals for a total of 60 min and then distance and movement direction of individual cells were plotted to calculate speed and velocity.
Measurement Neutrophil Chemotaxis In Vivo
Mice were subjected to application of metformin (125 mg/kg of body weight; intraperitoneal [IP]) for 12 h and 2 h before IP injections of W-peptide (0.43 mg/kg). In additional experiments, mice were treated with compound C (3 mg/kg, IP) or vehicle (saline) for 2 h prior to application of W-peptide. After 6 h, mice were euthanized and peritoneal lavages obtained using 10 mL of RPMI 1640 medium (without serum).
Phagocytosis Assay
Phagocytosis of fluorescent labeled E. coli or S. aureus by neutrophils was performed as described previously (39) . In brief, phagocytosis of fluorescently labeled bacteria by neutrophils pretreated with or without metformin (500 μmol/L, 2.5 h) was determined by adding tenfold excess of E. coli or S. aureus to the cells. To measure internalization of bacteria, fluorescent E. coli or S. aureus were incubated for 15 min at 37°C, and cells were then washed three times in ice-cold PBS. Next, cells were incubated with or without trypan blue solution (0.2% trypan blue, 20 mmol/L citrate, and 150 mmol/L NaCl, pH 4.5) for 1 min, then centrifuged, and the cell pellet was resuspended in PBS, and the amount of fluorescence was measured using flow cytometry.
In Vitro Killing-Activity Assay
Neutrophils (2 × 10 6 cells/mL) were incubated with ampicillin-resistant E. coli (2 × 10 7 /mL) in RPMI medium without serum for 90 min at 37°C. Next, 20 μL of cell/bacterial suspension was incubated with 480 μL Triton X-100 (0.1%) for 10 min to lyse neutrophils. Serial dilutions were then plated on agar plates with ampicillin and incubated overnight at 37°C. The number of bacterial colonies on agar plates was determined using colony counter software (Bio-Rad, Hercules, CA, USA).
Peritonitis-Induced Sepsis
The efficiency of bacterial eradication in vivo was performed as described previously (42, 43) . Mice were subjected to administration of metformin (125 mg/kg of body weight; IP) for 12 h, compound C (3 mg/kg of body weight; IP) or vehicle (PBS) for 2 h before IP injection of ampicillin-resistant E. coli (2 × 10 8 ). After 6 h, mice were euthanized and peritoneal lavages obtained using 10 mL RPMI 1640 medium without serum. The number of surviving bacteria was determined by incubation of 95 μL of peritoneal lavages with 5 μL of Triton X-100 (1%) for 10 min to lyse cells, and then serial dilutions were placed on agar plates with ampicillin and incubated overnight at 37°C. Bacterial colonies were counted using colony counter software (Bio-Rad).
Imaging Actin in Neutrophils
Neutrophils were incubated with 4% paraformaldehyde in PBS for 30 min at room temperature then washed with PBS and permeabilized with 0.1% Triton X-100/PBS for 4 min. The cells were then incubated with 3% BSA in PBS for 1 h, followed by the addition of Alexa Fluor 594-conjugated phalloidin (25 μL/mL) for 20 min at room temperature. After the cells were washed with PBS, they were mounted with emulsion oil solution containing DAPI to visualize nuclei. Confocal microscopy was performed as described previously, using a Leica DMIRBE inverted epifluorescence/ Nomarski microscope (Leica Microsystems, Wetzlar, Germany) outfitted with Leica TCS NT laser confocal optics (40) .
Western Blot Analysis
Western Blot analysis was performed as described previously (44, 45) . Briefly, cell lysates of murine bone marrow neutrophils (3.5 × 10 6 /well) were prepared using lysis buffer containing Tris pH 7.4 (50 mmol/L), NaCl (150 mmol/L), NP-40 (0.5%, vol/vol), EDTA (1 mmol/L), EGTA (1 mmol/L), okadaic acid (1 nmol/L) and protease inhibitors. Cell lysates were sonicated and then centrifuged at 10,000g for 15 min at 4°C to remove insoluble material. The protein concentration in the supernatants was determined using the Bradford reagent (BioRad) with BSA as a standard. Samples were mixed with Laemmli sample buffer and boiled for 15 min. Equal amounts of proteins were resolved by 8% to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred onto polyvinylidene fluoride (PVDF) membranes (Immobilon P; Millipore, Billerica, MA, USA). The membranes were probed with specific antibodies as described in the figure legends followed by detection with HRP-conjugated goat anti-rabbit IgG. Bands were visualized by enhanced chemiluminescence (Super Signal; Pierce Biotechnology, Rockford, IL, USA) and quantified by AlphaEaseFC software (Alpha Innotech, San Leandro, CA, USA). Each experiment was carried out two or more times using cell populations obtained from separate groups of mice.
Statistical Analysis
Statistical significance was determined by the Wilcoxon rank sum test (independent two-group Mann-Whitney U test) as well as Student t test for comparisons between two groups. Multigroup comparisons were performed using one-way analysis of variance (ANOVA) with Tukey post hoc test. A value of P less than 0.05 was considered significant. Analyses were performed on SPSS version 16.0 (IBM, Armonk, NY, USA) for Windows (Microsoft Corporation, Redmond, WA, USA).
RESULTS
Effects of AMPK Inhibition or Activation on Neutrophil Chemotaxis
In initial experiments, mouse neutrophil chemotaxis was determined using W-peptide, a mouse homolog of human IL-8. As shown in Figures 1A-C , W-peptide enhanced, in a dose-and time-dependent manner, neutrophil migration in transmigration chambers. To determine if neutrophil chemotaxis affected AMPK activation, neutrophils were incubated with W-peptide for 0, 20, 40 or 60 min and the amounts of total and phosphorylated AMPK were determined using Western blot analysis. As shown in Figure 1D , transient activation of AMPK was detected in neutrophils 20 min after exposure to W-peptide. Similar to the effects of W-peptide, enhanced chemotaxis and activation of AMPK was found in IL-8-treated HL-60 cells, a differentiated human neutrophil-like cell line ( Figures 1E, F) (41) . Average (mean ± SEM) of optical bend density was obtained from three independent experiments (*P < 0.05, compared with untreated). (E, F) HL-60 cells were treated with IL-8 for 60 min followed by chemotaxis assay (E) and Western Blot analysis (F) for phospho and total AMPK. Means ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, compared with untreated cells.
To evaluate the effects of AMPK activation on neutrophil chemotaxis, assays were performed using neutrophils that were left untreated (control) or that were incubated with the AMPK inhibitor compound C. Compound C dose dependently inhibited neutrophil chemotaxis (Figures 2A, B) . Additional experiments using the AMPK activators metformin or berberine demonstrated that exposure of neutrophils to such compounds resulted in enhanced chemotaxis ( Figure 2C ). The confirmatory experiments also were performed using control (scrambled) and specific siRNA to diminish expression of AMPKα1. As shown in Figures 2D  and 2E , siRNA mediated knockdown of AMPKα1 resulted in significant decrease in HL-60 chemotaxis. Although metformin and berberine stimulated AMPK activation and neutrophil motility, AICAR did not increase chemotaxis (data not shown) likely due to effects mediated by enzymatically produced ZMP in the AICAR-treated cells (46) (47) (48) .
AMPK Activation Prevents LPSInduced Inhibition of Chemotaxis
Previous studies have shown that engagement of TLR4 diminished IL-8-dependent chemotaxis of human neutrophils (49) . Similar to the previously reported results, we found that exposure of mouse bone marrow neutrophils to LPS also resulted in inhibition of neutrophil chemotaxis ( Figures 3A, B) . Western blot analysis showed that inhibition of neutrophil chemotaxis was associated with dose-and time-dependent decrease in LPS-induced AMPK phosphorylation ( Figures 3C, D) . To further determine the relationship between LPS and AMPK, neutrophils were treated with AICAR before or after exposure to LPS. As shown in Figures 3E and 4F , the addition of AICAR to the cell cultures, at either pre-or postexposure to LPS, was able to increase activity of AMPK.
Because metformin-induced activation of AMPK was shown to diminish LPSmediated neutrophil proinflammatory activation (31), we hypothesized that there might be similar effects of AMPK activation in preventing the inhibitory effects of LPS on chemotaxis. As shown in Figure 4A , incubation of neutrophils with metformin and LPS significantly improved chemotaxis as compared with that found when neutrophils were treated with LPS alone. Metformin increased neutrophil chemotaxis when included in the cell cultures before or after exposure of the cells to LPS. In additional experiments, the effects of metformin on LPS-associated diminishment of neutrophil velocity were determined using μ-slide for chemotaxis assay. As shown in Figures 4B and 4C , metformin increased neutrophil velocity and also prevented neutrophil immobilization after exposure to LPS. In contrast, treatment of LPS-exposed neutrophils with the AMPK inhibitor compound C resulted in significant inhibition of neutrophil chemokinesis.
R E S E A R C H A R T I C L E
Given our in vitro results showing that AMPK activation modulated neutrophil chemotaxis, we determined if activation or inhibition of AMPK can affect neutrophil chemotaxis in vivo. To examine this possibility, control mice or mice treated with metformin or compound C were then given an IP injection of W-peptide and the number of neutrophils migrating into the peritoneum was measured 5 h later ( Figure 4D ). As shown in Figure 4E , treatment with metformin before application of W-peptide was associated with an increased number of peritoneal neutrophils as compared with treatment with W-peptide alone. In contrast to metformin, administration of compound C diminished W-peptide-induced peritoneal accumulation of neutrophils.
AMPK Activation Facilitates Neutrophil-Dependent Bacterial Uptake and Killing
Although our experiments found that treatment with the AMPK activator metformin or the AMPK inhibitor compound C significantly affect neutrophil chemotaxis, the effects of AMPK activation on bacterial killing were not determined. In addition to the generation of ROS, phagocytosis is central in bacterial eradication. To measure phagocytosis, control (untreated) neutrophils or neutrophils treated with metformin or compound C were incubated with fluorescein isothiocyanate (FITC)-tagged E. coli or S. aureus and then subjected to flow cytometry. As shown in Figures 5A and 5B, pretreatment with metformin increased the ability of neutrophils to phagocyte bacteria. Next, we determined if activation or inhibition of AMPK can affect bacterial killing. To examine this possibility, neu- Cells also were treated with LPS (300 ng/mL) for 60 min followed by inclusion of AICAR (250 μmol/L) in the cultures for an additional 60 min. Means ± SD, n = 3, *P < 0.05, compared with neutrophils treated with LPS alone. ctr, Control; AIC, AICAR. trophils were left untreated or were incubated with metformin, AICAR or compound C. As shown in Figures 5C and  5D , both metformin and AICAR increased, whereas compound C diminished, bacterial killing. Results obtained from bacterial killing assays showed that a modest increase in the amount of bacteria was recovered after incubation of neutrophils with LPS ( Figures 5C, D) .
Previous studies have shown that signaling cascades downstream of AMPK activates regulation of mTORC1. Therefore, in additional experiments, neutrophils were treated with the specific mTOR inhibitor rapamycin. However, rapamycin exposure did not affect the ability of neutrophils to eradicate bacteria (see Figures 5C, D) .
AMPK Activation Enhances Bacterial Killing in Peritonitis-Induced Sepsis
Considering our in vitro results that AMPK activation with metformin increased neutrophil chemotaxis, as well as enhanced uptake and killing bacteria in vitro, we determined if metformin treatment can improve bacterial clearance in vivo. This possibility was examined using a murine model for peritonitis-induced sepsis (42, 43) . As shown in Figures 5E and 5F, there were significant decreases in the numbers of viable bacteria recovered from mice that received metformin as compared with controls. Of note, the number of peritoneal neutrophils was found to be increased, compared with the control group ( Figure 5G ).
AMPK Activation Stimulates Actin Rearrangement, Neutrophil Leading Edge Formation, and Diminishes LPS/TLR4-Mediated Inhibition of Neutrophil Chemotaxis
Although our experiments demonstrated that AMPK activation enhanced neutrophil chemotaxis and bacterial killing, the mechanism responsible for such effects was not delineated. AMPK activation induced by cellular exposure to metformin or AICAR results in cytoskeletal rearrangement (17) . As shown in Figure 6 , whereas significant decrease D 1 9 : 3 8 7 -3 9 8 , 2 0 1 3 | P A R K E T A L . | 3 9 3 
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Figure 4. Metformin diminished LPS-induced inhibition of neutrophil chemotaxis. (A)
Neutrophils were treated with metformin (met; 0 or 500 μmol/L) for 90 min and then LPS (0 or 300 ng/mL) for 60 min, or cells were first treated with LPS (300 ng/mL) for 60 min followed by inclusion of metformin (500 μmol/L) in the cultures for an additional 90 min. Neutrophil chemotaxis was then examined. Means ± SD, n = 3, *P < 0.05, **P < 0.01 compared with neutrophils treated with LPS alone. (B) Representative images show direction and distance (length of arrows) passed by the neutrophils a pretreated with metformin, LPS, compound C or combination of metformin and LPS. Panel (C) shows neutrophil velocity. Mean ± SEM, n ≥ 20, *P < 0.05, **P < 0.01 compared with control, ‡ P < 0.001 compared with metformin and § P < 0.001 compared with LPS alone. 
DISCUSSION
In the present studies, we found that activation of AMPK enhanced neutrophil chemotaxis and bacterial uptake, both essential components of bacterial killing. Recent studies, including results obtained from our laboratory (39) , have shown that metformin or other AMPK activators enhance cell mobility and also phagocytosis. For example, AMPK activation was associated with enhanced T cell chemotaxis or migration of epithelial cells (38, 50) . AMPK activation has also been shown to enhance the phagocytic ability of macrophages, including uptake of bacteria, synthetic beads or apoptotic cells (39) . These results are consistent with an ability of activated AMPK to facilitate microbial eradication through mechanisms that involve enhancement of neutrophil chemotaxis and/or bacterial uptake. Consistent with these previously reported findings, our present in vivo results showed that metformin effectively improved bacterial killing in vivo.
Severe sepsis is characterized by alterations in immunologic and host defense functions that include downregulation of neutrophil chemotaxis and phagocytosis (2, 16, 17, 51, 52) . Because AMPK activation in metformin-treated neutrophils prevented LPS-mediated inhibition of (55, 56) , in the present experiments, exposure of neutrophils to metformin did not prevent LPSdependent activation of mTOR. These results suggest that AMPK activation enhances neutrophil chemotaxis through mechanisms that involve suppression of TLR4-associated signaling pathways other than those involving mTOR. Although our results suggest that AMPK activation has beneficial effects on neutrophil function related to microbial clearance, it will be important to determine how AMPK activation affects such functions in additional cell populations, and also if AMPK activation can restore the diminished monocyte and T cell responses frequently found in sepsis (57) . Previous studies and results obtained from our laboratory have described antiinflammatory effects mediated by activated AMPK. Metformin, AICAR or berberine all were shown to diminish neutrophil and macrophage proinflammatory activation, as well as to decrease the severity of endotoxin-or ventilatorinduced acute lung injury (29, 31, 58) . Exposure of macrophages to antiinflammatory mediators, such as IL-10 or TGF-β, resulted in activation of AMPK followed by transition of the cells from the M1 to M2 phenotype (33) . Recent studies have shown that activated AMPK can also modulate the resolution of inflammatory conditions due to enhancement of the phagocytic ability of macrophages and neutrophils. In particular, AMPK activation increased the uptake of bacteria and enhanced efferocytosis, an essential process in the resolution of inflammation in which apoptotic cells are ingested and cleared by phagocytic cells (39, 59, 60) . Beneficial effects of AMPK activation also were related to improvement of vascular integrity in mice models for endotoxemia-induced ALI and to airway remodeling in asthma (34, 61) . In experimental models of diabetes, endothelial barrier function was preserved through mechanisms involving activation of AMPK (62) .
Recent studies have shown that AMPK phosphorylation was diminished upon exposure of cells to LPS. In particular, culture with LPS significantly decreased AMPK activity in neutrophils, peritoneal macrophages, Raw 264.7 cells, and endothelial cells (33, 34, 45, 63, 64) . The combination of LPS and saturated fatty acid palmitate also was shown to induce prolonged inactivation of AMPK in bone marrow macrophages (65) . Our present results indicate that in spite of inhibitory action of LPS, inclusion of AICAR or metformin was able to partially increase AMPK phosphorylation, even when included in cultures after cellular exposure to LPS (Figure 3 ) (45) .
Bacterial dissemination leading to multiorgan injury contributes to the high mortality rate associated with sepsis (10, 11, 19) . Whereas many patients survive the initial stages of sepsis, many will develop later clinical complications including nosocomial infections that lead to prolonged hospitalization. In spite of improved understanding of the mechanisms responsible for complications in sepsis, pharmacological approaches to prevent secondary infection and decrease morbidity and mortality associated with late infection have not been well characterized (57) . Metformin is approved for use in patients with diabetes with a wellestablished safety profile and known side effects and, for these reasons, may be considered for examination as a therapeutic approach in clinical trials of patients with sepsis. Although the early use of antibiotics is beneficial during sepsis, microbial products, as well as hostderived danger associated molecular pattern molecules (DAMPs) are still frequently present in the circulation and are likely to contribute to organ system dysfunction (66, 67) . For example, release of HMGB1, histones and mitochondrial proteins are known to increase the sever- (68) (69) (70) (71) . Of note, AMPK activators, including metformin, were shown to diminish acute inflammatory injury of lung or liver as well as decrease the release of DAMPs and improve mortality in experimental models of LPS-induced sepsis (5, 29, 36) . Although antibiotics are sufficient to kill bacteria, the combination of metformin and antibiotics may have additional benefit in sepsis, particularly as metforminstimulated neutrophils have increased chemotaxis and bacterial uptake.
